The non-pharmacologic nasal mist uses hydroxypropyl methylcellulose to form a protective physical barrier in the nasal passages, trapping and blocking airborne allergens.
Lerochol autoinjector is expected to launch by January 2027. The Food and Drug Administration (FDA) has approved a new once-monthly autoinjector presentation of Lerochol ® (lerodalcibep-liga), a third ...
Nearly 1 in 4 patients treated with lecanemab for mild cognitive impairment or mild Alzheimer disease (AD) with confirmed amyloid pathology develop amyloid-rela ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results